HedgeMountain

Highvista Strategies LLC

Boston, MA · CRD 155759
Hedge fund manager

Highvista Strategies LLC is an SEC-registered investment adviser based in Boston, MA that reports managing 23 hedge funds on Form ADV. It reports $9.1 billion in regulatory assets under management. Its private funds, of all types, hold $7.6 billion in gross assets. Its disclosed U.S. stock holdings returned an estimated +25.5% 2026 YTD through Jun 30 (S&P 500: +9.5%), based on 13F filings. Over a longer period they returned an estimated +99.5% from Q3 2024 to Q2 2026, compared with +37.2% for the S&P 500, based on 13F filings.

Regulatory assets under management
$9.1 billionForm ADV Item 5.F
Gross assets of private funds
$7.6 billionAll private fund types, Form ADV
Hedge funds managed
2340 private funds in total
Employees
80Form ADV Item 5.A
Registration
SEC-registered adviserCRD 155759
Latest Form ADV
03/31/2026Disciplinary disclosures: none reported

Estimated 13F portfolio performance

Est. 2026 YTD+25.5%Through Q2 2026 · S&P 500 +9.5%
Est. 2-year return+99.5%Q3 2024 – Q2 2026
S&P 500+37.2%Same quarters, price only
13F holdings$438.6 million147 positions, 2026-06-30
$95$147$199Q3 2024Q1 2025Q3 2025Q1 202613F est. $199S&P 500 $137
QuarterEst. 13F returnS&P 500
Q2 2026+22.6%+14.8%
Q1 2026+2.4%-4.6%
Q4 2025+27.1%+2.4%
Q3 2025+18.7%+7.8%
Q2 2025+11.4%+10.4%
Q1 2025-7.6%-4.5%
Q4 2024-4.9%+2.1%
Q3 2024+7.7%+5.4%

Estimate of the firm's disclosed long U.S. stock portfolio from its quarterly 13F filings, holding each quarter-end portfolio to the next quarter-end at prices implied by all 13F filers. It is a price return before dividends and fees, ignores shorts, options, bonds, cash and trading within the quarter, and is not the return of any fund. Disclosures

Largest disclosed holdings

  • Invesco DB Commodity Index Tra$28.2 million
  • Abivax SA SP ADS$15.1 million
  • Revolution Medicines Inc$12.5 million
  • 24477v105$11.4 million
  • Immunovant Inc$10.7 million
  • Praxis Precision Medicines I$10.1 million
  • Relay Therapeutics Inc$9.5 million
  • Alkermes PLC$9.4 million
  • Vaxcyte Inc$8.7 million
  • Tango Therapeutics Inc$8.1 million

As of 2026-06-30, from 13F filing by HighVista Strategies LLC.

Hedge funds filing Form D (9)

Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.

From SEC filings. Firm data comes from the SEC's Form ADV data as of Oct 2, 2026; performance estimates come from Form 13F. HedgeMountain has not verified this information, and it is not an offer, solicitation or recommendation. Full disclosures